Due Diligence of course...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
144 for you jay, cheer's Diva:)
#134 for you, ty cheer's diva
ty, 715 back at ya, Cheer's diva
NVLX Medical Marijuana Sciences' Scientific Advisory Board Chairman Dr. Mark L. Rabe Educates Professional Fiduciaries on the Benefits of Medical Marijuana http://www.stockwatch.com/News/Item.aspx?bid=U-z10078495-U%3aNVLX-20140428&symbol=NVLX®ion=U
PLPL - Petitions South Africa Department of Health for License to Conduct Cannabis Research http://www.stockwatch.com/News/Item.aspx?bid=U-et1174138779-U%3aPLPL-20140428&symbol=PLPL®ion=U
Forest Laboratories FRX to Acquire Furiex Pharmaceuticals FURX for $1.1 Billion in Cash to Build on a Lead... http://finance.yahoo.com/news/forest-laboratories-acquire-furiex-pharmaceuticals-111500606.html?soc_src=mediacontentstory
ouch- OGXI OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for M... http://finance.yahoo.com/news/oncogenex-announces-top-line-survival-111000248.html?soc_src=mediacontentstory
GSK Theravance announce Anoro Ellipta available in U.S. for treatment of COPD
GlaxoSmithKline (GSK) and Theravance (THRX) announced that Anoro Ellipta, the first once-daily product approved in the U.S. that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease, or COPD, is now available to retail pharmacies in the U.S. Under the terms of its 2002 LABA collaboration agreement with GSK, Theravance agreed to make a milestone payment of $30M to GSK following the launch of Anoro Ellipta in the U.S.
#247 for you Affix, ty ty cheer's
#219 for you thank you:)
#99 for you Johnnyblaze:)
#98 for you dspin, cheer's
#166 for you:) Cheer's
#126 for you num1, ty ty for the follow:)
thank you #169 for you:)
Cheer's
Diva
#98 for you:)
Cheer's
Diva
ty, 136 for u:)
Good Morning:) anyone need a follow, hit me up:) cheer's and go green!
BIND Therapeutics barasertib data positive, says JMP Securities
JMP Securities notes that pre-clinical studies of BIND's barasertib showed enhanced anti-tumor activity and reduced bone marrow toxicity. The firm thinks the company could overcome the need for lengthy drug infusion and high rates of febrile neutropenia, shown in a previous studiy, by extending the half-life of the drug. The firm reiterates a $30 price target and Outperform rating on the stock.
http://www.theflyonthewall.com/permalinks/entry.php/BINDid1992466/BIND-BIND-Therapeutics-barasertib-data-positive--says-JMP-Securities
CTIX Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae http://finance.yahoo.com/news/study-shows-cellceutix-antibiotic-active-103000797.html?soc_src=mediacontentstory via @YahooFinance
NBS NeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc. http://finance.yahoo.com/news/neostem-announces-definitive-agreement-acquire-110000900.html?soc_src=mediacontentstory via @YahooFinance
ADXS Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its... http://finance.yahoo.com/news/japan-patent-office-issues-advaxis-113000587.html?soc_src=mediacontentstory via @YahooFinance
PTLA Portola announces publication of Phase 3 APEX study design, rationale http://finance.yahoo.com/news/portola-announces-publication-phase-3-121241337.html?soc_src=mediacontentstory via @YahooFinance
BMRN BioMarin says FDA extends Kuvan market exclusivity by six months http://finance.yahoo.com/news/biomarin-says-fda-extends-kuvan-122233028.html?soc_src=mediacontentstory via @YahooFinance
PLPL Extracts Could Further Shape Marijuana Debate
NEW YORK, NY -- (Marketwired) -- 04/11/14 Plandaí Biotechnology (OTCQB: PLPL) has a deal in place to brand and market its future cannabis extracts under the Diego Pellicer Gold label, and it could be those extracts and the company's work with cannabinoids that help shape public opinion in favor of using the drug medicinally. A Pew Research Center survey released last week found that 75 percent of Americans say they feel the legal sale and use of marijuana is inevitable whether they support it or not. While support for marijuana grows, Plandaí and its extracts could go a long way toward changing the minds of the drug's opponents.
In the survey, 54 percent of respondents favored legalizing the use of marijuana which is a dramatic change from just 4 years ago when in the same survey, only 41 percent thought pot should be legal. Make no mistake about it attitudes are shifting in favor of marijuana in this country, and recent interest is likely due to CNN Chief Medical Correspondent Sanjay Gupta's "Weed" documentaries that are educating more Americans on the realities of cannabis. "Weed" documentaries can be seen commercial free at www.stockmarketmediagroup.com/media.
Dr.Gupta himself was once a staunch opponent of legalizing marijuana, but he has since become a strong advocate for the use of cannabis. In those documentaries, Dr. Gupta has highlighted just how powerful the use of cannabinoids can be as a treatment for such things as seizures, pain management, cancer and many others.
Plandaí produces highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, and will explore the use of both THC and cannabinoids to develop extracts and to pursue various pharmaceutical and nutraceutical applications. Dr. Gupta and a majority of Americans in general agree with Plandaí's CEO Roger Duffield who said, "The medicinal opportunities associated with phyto-cannabinoids are simply too great to ignore."
http://www.stockwatch.com/News/Item.aspx?bid=U-i1106142-U%3aPLPL-20140411&symbol=PLPL®ion=U
NVLX Engages ViruSure to Establish Cell Banks for Phase 2b Clinical Trials in Pancreatic Cancer
SILVER SPRING, Md., April 10, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that it has signed a Master Services Agreement with ViruSure GmbH, located in Vienna, Austria, to develop and maintain Master, Working and End of Production Cell Banks. These cell banks are necessary steps in the production of the cells to be encapsulated using the Cell-in-a-Box® technology for Nuvilex's Phase 2b clinical trials in advanced, inoperable pancreatic cancer to be conducted in Australia.
"ViruSure has previous experience in handling the exact cell line that will be used in our Phase 2b clinical trials, which was a major factor in Nuvilex selecting ViruSure for this important step in our preparations for these trials," said Kenneth L. Waggoner, CEO and President of Nuvilex. "This decision was further supported by our on-site inspection of the ViruSure facilities and the excellent historical relationships between ViruSure's key personnel with our partners at Austrianova. ViruSure has years of experience in producing and maintaining cell banks and is an industry leader in this arena."
"We are delighted to be partnering with Nuvilex on such an important project and in helping to bring this much needed therapy for such a devastating disease as pancreatic cancer to the clinic," stated Andy Bailey, CEO and co-founder of ViruSure.
The cells that will make up the Master, Working and End of Production Cell Banks will be those that convert the anticancer drug ifosfamide into its cancer-killing form. These therapeutic cells will be shipped to ViruSure for propagation. First a Master Cell Bank will be established where aliquots of cells will be stored frozen. Cells from the Master Cell Bank will be propagated to make up the large number of cells that will comprise the Working Cell Bank. Ultimately, cells from the Working Cell Bank will be encapsulated using the Cell-in-a-Box® live cell encapsulation technology. An End of Production Cell Bank will then be made from the final product for quality control purposes. The encapsulated cell product, together with ifosfamide, forms Nuvilex's treatment for pancreatic cancer.
http://www.stockwatch.com/News/Item.aspx?bid=U-z10076266-U%3aNVLX-20140410&symbol=NVLX®ion=U
OMED - OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Canc... http://finance.yahoo.com/news/oncomed-presents-data-multiple-anti-123000270.html?soc_src=mediacontentstory via @YahooFinance
HALO - Halozyme Announces Preclinical Data Presentations At The Association Of Cancer Research Annual Me... http://finance.yahoo.com/news/halozyme-announces-preclinical-data-presentations-130000549.html?soc_src=mediacontentstory via @YahooFinance
HEB - Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety P... http://finance.yahoo.com/news/hemispherx-biopharma-announces-publication-enlarges-123000986.html?soc_src=mediacontentstory via @YahooFinance
NVLX - Medical Marijuana Sciences' Dr. Mark L. Rabe Speaks at ASA Medical Cannabis Unity Conference in Washington DC
SILVER SPRING, Md., April 8, 2014 (GLOBE NEWSWIRE) -- Medical Marijuana Sciences, Inc., a subsidiary of Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that Dr. Mark L. Rabe's presentation at the National Medical Cannabis Unity Conference, held this past weekend in Washington DC, prompted numerous questions and a lively discussion on Nuvilex's proprietary Cell-in-a-Box® platform and how Medical Marijuana Sciences is working to combine it with the cancer-fighting properties of cannabinoids.
The conference, hosted by Americans for Safe Access (ASA) and titled, "Navigating Medicinal Cannabis in the Mainstream," was attended by several hundred medical marijuana patients, parents of pediatric patients, educators, veterans, physicians, and other individuals calling for a stronger commitment to the safe, medicinal use of cannabis.
"It was a profound and humbling experience to see the dedication, commitment and sacrifice put forth by the members and sponsors of the ASA. This group of individuals has fought tirelessly to provide patients with safe access to cannabis-based medicine," said Dr. Rabe. "It was also encouraging to hear recently from the federal government comments about the potential of reclassifying or declassifying cannabis from its present status, which would provide the opportunity to advance scientific research and further the development of potentially life-saving cannabinoid-based therapies."
Dr. Rabe's presentation, "Targeted Cannabinoid-based Chemotherapy Utilizing Cell-in-a-Box® Technology," addressed new research that Medical Marijuana Sciences is undertaking in the fight against pancreatic and brain cancers and highlighted how further research is needed to help prevent the tens of thousands of deaths that occur each year as a result of these two diseases.
"Dr. Rabe is Chairman of Medical Marijuana Sciences' Scientific Advisory Board and is a well-respected veteran in the discussion of medical marijuana. His insight on the potential use of cannabinoids, particularly in combination with our parent company's Cell-in-a-Box® technology to treat these difficult cancers, has proven vital to our evolution as a company," said Tim Matula, President of Medical Marijuana Sciences. "Recent surveys have demonstrated that oncologists, among other top medical practitioners, have a keen interest in the potential use of cannabinoids both in compassionate care and in the fight against cancer and other deadly diseases; many have spoken and continue to speak openly about its decriminalization and the possible research applications that could result."
About Medical Marijuana Sciences:
Medical Marijuana Sciences, Inc. is the newest wholly-owned subsidiary of Nuvilex, Inc. It was established in early 2013 with the initial mission to develop treatments based on constituents of cannabis for two of the most serious and deadly forms of cancer, namely brain and pancreatic cancers.
http://www.stockwatch.com/News/Item.aspx?bid=U-i1104909-U%3aLIVE-20140408&symbol=LIVE®ion=U
PLPL Qualifies for Grant From South African Department of Trade & Industry
2014-04-08 08:55 ET - News Release SEATTLE, WA(eTeligis.com)
Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has qualified for and submitted the necessary paperwork to receive a grant from the South African Department of Trade and Industry (DTI). DTI grants are awarded based on qualifications relating to capital investment in new industry. The Company's extraction and processing factory in the Mpumalanga province in northern South Africa is considered a qualifying facility. DTI representatives will be touring the facility in the first week of May.
According to the DTI website (http://www.thedti.gov.za/about_dti.jsp), their strategic objective is to facilitate transformation of the economy to promote industrial development, investment, competitiveness and employment creation. The grant for which Planda qualifies is based on a fixed percentage of actual capital invested in the project. Depending on the final cost of the Senteeko manufacturing facility and the percentage of award as determined by the legislature, the grant is expected to be between 14-26 million Rands ($1.3-2.5 million US). The final amount is expected to be determined over the coming 90 days with the award being paid later in 2014.
Chairman and Chief Executive Officer Roger Duffield commented, "The South African government has been among our strongest supporters, first with the $13 million government-backed loan from the Land and Agriculture Bank, and now with an additional $1.3 to $2.5 million grant to help defray the cost of building our production facility. It is a testament to their belief not only in our technology but also our efforts to revitalize the region by creating jobs and operating under a zero carbon footprint model. The grant money will be useful in supporting our operations as the factory comes online and sales begin to ramp up in the coming months."
Planda first product to market will be Phytofare Catechin Complex, which includes the entire catechin profile derived from live green tea that is grown and processed on the Company's 8,000 acre Senteeko estate in South Africa. Later in 2014, and pending the results of a human clinical trial for treating cold and flu symptoms, the Company will begin producing Phytofare Limonoid Glycoside Complex, which contains citrus bioflavonoids that will also be extracted at the Senteeko facility using lemons bought from neighboring farms until its own lemon trees reach maturity.
About Planda Biotechnology, Inc.
Planda Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com
http://www.stockwatch.com/News/Item.aspx?bid=U-et971018422-U%3aPLPL-20140408&symbol=PLPL®ion=U
Please say a prayer for me today... Stitches and tubes come out and it's the moment of truth. For those of you that were with me on the last surgery know, the wound did not stay together... and I am scared. He did stitches vs staples, bikini vs up and down this time and I am praying it works and no wound vac is needed. Love to all and thank you... PLEASE PLEASE Dear Lord!
Awesome! she smiled... She is home and recovering and will be back soon!!! all went well
StocksDiva - Mom update: She is out of surgery and settled in her room. Still haven't spoken to the surgeon. But everything went well. Still has ostomy, but everything else was fixed. At least that's what the recovery nurse said. Prayers for a speedy recovery.
this is her daughter, thank you all.
PLPL Announces Favorable Results for Human Clinical Trial
2014-03-20 09:18 ET SEATTLE, WA(eTeligis.com)Planda Biotechnology, Inc. (OTCQB:PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced favorable results from a recent human clinical trial involving a topical preparation of its Phytofare Catechin Complex. The study, which was undertaken by Prof. Banie Boneschans, North West University in Potchefstroom, South Africa, one of the leading research universities on the continent, was a double-blind study that tested the anti-aging properties of Phytofare. Specifically, the trial tested surface parameters (scaling and roughness), skin hydration, and skin elasticity.
The results, which were released to the company on March 17, stated that Phytofare yielded "statistically significant" results when compared to a baseline product.The trial involved 35 female Caucasian test subjects who applied two topical creams daily, the only difference being that one contained Phytofare, to skin patches which were tested at 14, 28, and 42 days.
The process of aging has a direct impact on the status of the skin surface. Skin imperfections, such as wrinkles and scaliness, reflect light differently than smooth, younger skin. A UVA-light camera with a black-and-white video sensor was used to photograph the skin surface and then measured the differences in texture. The study showed that the addition of Phytofare improved skin roughness by as much as 15% at 28 days, and a reduction in scaliness of the stratum corneum by 20%.Both of these measures were deemed "statistically significant" by the researcher.
In testing skin hydration, a Corneometer(R) was used to measure the change in the dielectric constant due to skin surface hydration.The study showed the Phytofare increased skin hydration by 15% at both 28 and 42 days, compared to .9% and 7.8% for the base product.The study pointed out that skin hydration improved significantly at 28 days and then maintained that level throughout the study.
The elastic properties reflect the skin's ability to return to its initial position after deformation and can be effected by chronological- and photo aging of the skin. Skin elasticity was evaluated by means of a Cutometer(R).The study showed an average improvement in skin elasticity of 1% at 42 days, though there was significant inter subject variation which rendered the results inconclusive with a recommendation for a larger sample size and longer duration for a future study.
Planda Vice President Jamen Shively commented, "This study validates the last decade of research and illustrate the benefits of enhanced bioavailability.We envision our Phytofare topical formulation serving as the backbone for a host of potential cosmetic products and look forward to sharing the results with our distribution partners as we near release of Phytofare to the market."
The company has placed an abstract of the study on its website:www.plandaibiotech.com
http://www.stockwatch.com/News/Item.aspx?bid=U-et54567527-U%3aPLPL-20140320&symbol=PLPL®ion=U
NVLX Contracts With Austrianova for cGMP-Compliant Cell-in-a-Box(R) Encapsulation of Cells for Clinical Trials
NEW YORK, NY -- (Marketwired) -- 03/20/14 LiveDeal, Inc. (NASDAQ: LIVE) has generated a lot of attention since entering the online deal space and that attention has been well deserved. The company's instant, real-time concept makes more sense for users than the model used by long-time industry leaders like Groupon and others. Quite simply when business owners need more customers, they will create a promotion with an online deal site to help introduce their brand to potential consumers. LiveDeal launched its online deal platform in the restaurant industry, and with it, it's giving those restaurants the opportunity to reach customers immediately and in real-time.
The introduction of this instant, real-time model gives www.livedeal.com plenty of potential as an on-going technology platform into the future. LiveDeal recently announced that it is ramping up its deal procurement team so that it can quickly grab market share. It is clear that the first step the company is taking is to build an audience. In technology, the name of the game is potential. Instagram, for instance, had 30 million users when it was acquired, but to arrive at a fair value for acquisition, the technology's future potential had to be included in the evaluation. Instagram has proven that potential with close to 150 million users.
In technology, since most platforms are so scalable, those looking to acquire these technologies project 2, 3 and 5-years out in time to see where the product could be, and usually pay a multiple based on future potential, not actual results at the time. This bodes well for LiveDeal and its online and mobile deal engine, livedeal.com.
LiveDeal seems to understand that the name of the game is potential and that building a technology's popularity by increasing its number of users could equate to more and more dollars in the company's future. With each major city that the company has added to its platform, there is the market to add thousands of new restaurants to create promotions and potentially millions of new consumers to view and use those real-time deals.
Because LiveDeal's platform gives the restaurant owner all of the control, creates a direct relationship between merchant and consumer and eliminates the middleman by letting consumers pay for the promotions found on livedeal.com directly to the restaurant, the platform has to be taken seriously in the industry.
Other online deal sites in the industry don't offer all of these advantages, so using a media campaign to drive more and more users to the company's platform should only serve to make this model the way merchants advertise promotions and consumers find their deals well into the future.
http://www.stockwatch.com/News/Item.aspx?bid=U-z10073394-U%3aNVLX-20140320&symbol=NVLX®ion=U
Cool PLPL Video of the test Stage 1 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa
PLPL Completes Stage 1 of Senteeko Phytofare Factory, Readies for Production http://www.stockwatch.com/News/Item.aspx?bid=U-et1458056597-U%3aPLPL-20140318&symbol=PLPL®ion=U
PLPL is one of the few cannabis OTC companies that is eagerly anticipating the legalization of medical marijuana nationwide. Currently the drug is legal medicinally in 20 states and Washington, D.C., but in this election year, that number is likely to grow. In each national election year, the frenzy begins again and with it, a growing momentum that has the U.S. drawing closer to a nationwide acceptance http://www.stockwatch.com/News/Item.aspx?bid=U-i1095827-U%3aPLPL-20140306&symbol=PLPL®ion=U
MDVN Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Ch... http://finance.yahoo.com/news/astellas-medivation-submit-supplemental-drug-110000020.html?soc_src=mediacontentstory via @YahooFinance